ArticleAnnals of surgical oncology2025
Combined Portal and Hepatic Vein Embolization Produces Greater Hypertrophy than Portal Vein Embolization Alone with Similar Post-Hepatectomy Outcomes and is not Impacted by Hepatic Artery Infusion Chemotherapy.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pushing the boundaries of surgical resectability in colorectal liver metastases: the advancing role of two-stage hepatectomy.Hepatobiliary surgery and nutrition · 2026Article
- Liver venous deprivation before major hepatectomy-promising but still a work in progress.Hepatobiliary surgery and nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundCombined portal and hepatic vein embolization (cPVE-HVE) induces hypertrophy of future liver remnant before hepatectomy. We compared liver hypertrophy and post-hepatectomy outcomes between cPVE-HVE and portal vein embolization (PVE) alone. PATIENTS AND
methodsConsecutive patient outcomes after cPVE-HVE and PVE were compared across all pathologies for degree of hypertrophy (DH), kinetic growth rate (KGR), impact of hepatic artery infusion chemotherapy (HAIC), and post-hepatectomy complications at a single center.
resultsThe study cohort included 305 patients, 250 underwent PVE and 55 underwent cPVE-HVE. Pre-embolization future liver remnant (FLR) was 28% versus 32% (p < 0.001) for cPVE-HVE and PVE. Post-embolization DH (11.3% versus 9.4%; p = 0.001) and KGR (3.33% versus 2.29%; p < 0.001) were significantly greater for cPVE-HVE over shorter interval (22 versus 28 days; p = 0.007). HAIC was used in 42% (n = 23) of patients before cPVE-HVE and did not impact hypertrophy. Post-hepatectomy outcomes were similar between cPVE-HVE (n = 38) and PVE (n = 250) cohorts. Rates of transfusion (39% versus 40%; p > 0.9), liver failure (7.9% versus 9.2%, p = 0.6), grade 3-5 complications (42% versus 42%, p > 0.9), 90 day all-cause mortality (5.3% versus 3.6%, p = 0.6), and median hospitalization (7 versus 8 days; p = 0.067) were not significantly different.
conclusionscPVE-HVE was associated with greater hypertrophy than PVE alone, with similar post-hepatectomy outcomes. cPVE-HVE after HAIC was safe with similar hypertrophy. Randomized clinical trial evidence is needed to clearly delineate indication for cPVE-HVE and assess postoperative outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.